Trimetazidine

  • Procedure started
  • Under evaluation
  • CHMP opinion
  • European Commission final decision
Current status
European Commission final decision

Overview

On 21 June 2012, the European Medicines Agency completed a review of the safety and effectiveness of trimetazidine following concerns over its effectiveness and reports of movement disorders such as Parkinsonian symptoms with these medicines. The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits continue to outweigh the risks in patients with angina pectoris but that treatment should be restricted to add-on to existing treatments in patients who are not adequately controlled by or who are intolerant to other medicines for angina pectoris. For the symptomatic treatment of tinnitus, vertigo and visual-field disturbances, the CHMP concluded that the benefits no longer outweigh the risks and that these uses should no longer be authorised. In addition, the Committee recommended new contraindications and warnings to reduce and manage the possible risk of movement disorders, associated with the use of this medicine.

Key facts

About this medicine
Approved name
Trimetazidine
International non-proprietary name (INN) or common name
trimetazidine
Associated names
Vastarel
About this procedure
Current status
European Commission final decision
Reference number
EMEA/H/A-31/1305
Type
Article 31 referrals

This type of referral is triggered when the interest of the Union is involved, following concerns relating to the quality, safety or efficacy of a medicine or a class of medicines.

Key dates and outcomes
CHMP opinion date
21/06/2012
EC decision date
03/09/2012

All documents

  • List item

    Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution) (PDF/59.57 KB)


    First published: 22/06/2012
    Last updated: 17/10/2012
    EMA/412151/2012

  • European Commission final decision

  • List item

    Trimetazidine - Article 31 referral - Assessment report (PDF/499.39 KB)

    Adopted

    First published: 17/10/2012
    Last updated: 17/10/2012

  • List item

    Trimetazidine - Article 31 - Annex I (PDF/373.34 KB)


    First published: 17/10/2012
    Last updated: 17/10/2012

  • List item

    Trimetazidine - Article 31 - Annex II (PDF/99.48 KB)


    First published: 17/10/2012
    Last updated: 17/10/2012

  • List item

    Trimetazidine - Article 31 - Annex III (PDF/95.27 KB)


    First published: 17/10/2012
    Last updated: 17/10/2012

  • List item

    Trimetazidine - Article 31 - Annex IV (PDF/30.55 KB)


    First published: 17/10/2012
    Last updated: 17/10/2012

  • Description of documents published

    Please note that some of the listed documents apply only to certain procedures.

    • Overview - lay-language summary of the stage of the procedure
    • Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
    • Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
    • List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
    • Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
    • List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
    • List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
    • Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
    • Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
    • Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
    • Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
    • Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
    • Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
    • Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
    • Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)

    Note that older documents may have different titles.

    How useful was this page?

    Add your rating
    Average
    3 ratings
    3 ratings
    2 ratings